Abstract: A key bottleneck in the production of pharmaceuticals is in the formation of crystals from solution. The control of the crystal size distribution can b ecritically important for e cient downstream operations such as ltration and drying, and product e ectiveness (e.g., bioavailability, tablet stability). This paper provides an overview of recent developments in the identi cation of pharmaceutical crystallization processes. This includes descriptions of recent activities in sensor technologies, model identi cation, experimental design, and robustness analysis of pharmaceutical crystallization processes.
INTRODUCTION
A key bottleneck in the production of pharmaceuticals is in the formation of crystals from solution. For e cient downstream operations (such as ltration and drying) and product e ectiveness (e.g., bioavailability, tablet stability), the control of the crystal size distribution can b ecritically important. Also important are the crystal purity and the crystal shape. The crystal size and shape a ect the dissolution rate, which is important in most pharmaceutical applications. In the pharmaceutical industry, the relative impact of drug b e n e tversus adverse side e ects can depend on the dissolution rate. Control of crystal size and shape can enable the optimization of the dissolution rate to maximize the bene t while minimizing the side e ects. Po o rcontrol of crystal size and shape can result in unacceptably long ltration or drying times, or in extra processing steps, such as recrystallization or milling. Purity is especially important in the f o o dand pharmaceutical industries, in which the crystals will b econsumed. Figure 1 shows the variability in crystal shape that can occur at a single time instance in a pharmaceutical crystallizer. This particular drug, paracetamol (also known as acetaminophen), can have three di erent crystal morphologies when grown from a paracetamol-water solution (Finnie et al., 1999) . The fundamental driving force for crystallization from solution is the di erence b e t ween the chemical p o t e n tial of the supersaturated solution and that of the solid crystal face (Kim and Myerson, 1996 Mullin and Sohnel, 1977) . It is common to simplify this by representing the nucleation and growth kinetics in terms of the supersaturation, which is the di erence b e t ween the solute concentration and the saturated solute concentration. Supersaturation is typically created in pharmaceutical crystallizers by cooling and/or by adding a solvent for which the solute has a lower solubility.
The challenges in the processing of pharmaceutical crystals are signi cant. First, there are significant uncertainties associated with their kinetics. Part of the di culty is that the kinetic parameters can b ehighly sensitive to small concentrations of contaminating chemicals, which can result in kinetic parameters that vary over time. Also, many pharmaceutical crystals are su ciently fragile that the crystals break after formation, or the crystals can agglomerate or have erosion or other surface e ects that are di cult to characterize. Another signi cant source of uncertainty in industrial crystallizers is associated with mixing. Although crystallization models usually assume perfect mixing, this assumption is rarely true for an industrial-scale crystallizer. Crystallization processes are highly nonlinear, and are modeled by coupled nonlinear algebraic integro-partial di erential equations. The very large numb e rof crystals is most e ciently described by a distribution (e.g., see Figure 2 ). For the case of distribution in shape as well as overall size, there are at least three independent variables in the equations. Simulating these equations can b echallenging because the crystal size distribution can b eextremely sharp in practice, and can span many orders of magnitude in crystal length scale (0.01 nm to 200 m) and time scale (20 s to 200 min). The short time scales are especially relevant in impinging jet crystallizers, in which crystal nuclei are formed directly from solution under conditions of very high supersaturation. Another challenge in crystallization is associated with sensor limitations. The states in a crystallizer include the temperature, the solution concentration, and the crystal size and shape distribution. The solution concentration must b emeasured very accurately to specify the nucleation and growth kinetics. Obtaining an accurate measurement of the full crystal size distribution (CSD) is even more challenging. Hence it is desirable to estimate the states from the noisy measurements that are available. This paper reviews e orts towards the control of pharmaceutical crystallization processes. A description of the current status of sensor technologies is followed by a description of an approach for model identi cation and experimental design. Fig. 2 . The crystal size distribution for prism-like crystals with two characteristic length scales (r 1 and r 2 ) and nucleation and growth kinetics identi ed from laboratory data . Next, recent advances are discussed in the robustness analysis of nonlinear distributed parameter systems, focusing on applications to crystallization processes.
SENSOR TECHNOLOGIES
Measurements of b o t hthe solution concentration and the crystal size distribution are necessary for e ective estimation and control.
Solution Concentration Measurement
The nucleation and growth rates are strongly dependent on the solution concentration, making its measurement necessary for estimating kinetic parameters and highly useful for feedback control. A signi cant advantage of attenuated total reection (ATR) Fourier transform infrared (FTIR) spectroscopy over most other methods for solution concentration measurement is the ability to provide simultaneous measurement of multiple chemical species. The feasibility of ATR-FTIR spectroscopy for the in situ measurement of solution concentration in dense crystal slurries has been demonstrated (Dunuwila et al., 1994 Dunuwila and Berglund, 1997 Lewiner et al., 1999 Lewiner et al., 2001 . In ATR-FTIR spectroscopy, the infrared spectrum is characteristic of the vibrational structure of the substance in immediate contact with the ATR immersion probe. The crystal of the ATR probe is selected so that the depth of penetration of the infrared energy eld into the solution is smaller than the liquid phase barrier b e t ween the probe and solid crystal particles. Hence when the ATR probe is inserted into a crystal slurry, the substance in immediate contact with the probe will b ethe liquid solution of the slurry with negligible interference from the solid crystals. solution at di erent concentrations and temperature, in ascending order: 0.010 g/g water (33 C), 0.015 g/g water (38 C), 0.020 g/g water (43 C), 0.025 g/g water (48 C), 0.030 g/g water (53 C), and 0.035 g/g water (58 C). The combination of ATR-FTIR spectroscopy with advanced chemometrics analysis can measure solution concentrations with accuracy as high as 0:1 wt% in dense crystal slurries (Togkalidou et al., 2000 Togkalidou et al., 2001b . The absorbances measured in the mid-infrared range using ATR-FTIR are usually linearly related to the solution concentration, so nonlinear chemometrics analysis such as used in near-infrared spectroscopy (Amrhein et al., 1996) is usually unnecessary. The ATR-FTIR approach has been applied to a numb e rof complex pharmaceutical compounds in academic and industrial laboratories. This includes applications to several polymorphic crystal systems with multiple solvents and solutes at Merck . Figures 3 and 4 show the ATR-FTIR spectra and solubility curve for the paracetamol-water system , which is an especially challenging system due to the relatively low solubility of paracetamol in water. The reliability and consistency of this approach are expected to result in even more applications to pharmaceutical crystallization processes in future years, both in academia and industry.
On-line Crystal Size Distribution Measurement
Our laboratory crystallizer is equipped with a laser backscattering device and a video microscope which are used to measure the crystal size distribution in situ. A signi cant advantage of this approach is the ability to take measurements in slurries with high crystal solids density, as occurs in operations typical of the pharmaceutical industries. The laser backscattering approach is based on inserting a probe directly in the crystallizer, focusing a laser beam forward through a window in the , has been applied to numerous pharmaceutical crystallizers (Togkalidou et al., 2001c) . Like any laser-based method applied to a crystal slurry, a transformation is required to relate the collected laser light to the crystal size distribution. The FBRM instrument measures the chord length distribution (e.g., see Figure 5 ) as the laser b e a memitted from the sensor randomly crosses two edges of a particle, with this distance b e i n gthe chord length. There have b e e ne orts to relate the chord length distribution to the crystal size distribution, b o t hby the Lasentec company and by some independent researchers (Ruf et al., 2000 Tadayyon and Rohani, 1998) . This relationship is dependent on a large numb e rof operating variables, whose e ects are not easy to model theoretically, especially for dense crystal slurries (Monnier et al., 1996 Monnier et al., 1997 A weakness of the laser backscattering and related laser-based sensors is that the distribution of crystal shape cannot b edirectly determined. For example, a collection of rod-like crystals are characterized mathematically by a two-dimensional distribution (one dimension b e i n g the length, and the other dimension being the breadth), but the light scattering instruments only provide one-dimensional distributions. It is impossible to uniquely determine a two-dimensional distribution from a one-dimensional distribution. The shape information is averaged out to obtain a onedimensional distribution. An alternative method for measuring the crystal size distribution is through p e r i o d i csampling, video microscopy, and image analysis (Puel et al., 1997 Rawlings and Patience, 1999) . Sampling can b eproblematic in an industrial environment. A commercial instrument that has become available is the Lasentec Particle and Vision Measurement (PVM) system, in which images of crystals in solution are obtained using a probe inserted directly into the dense crystal slurry. This video microscope can collect 10-30 images a second, providing two-dimensional snapshots of the crystals in real time. On-line video microscopy can image crystals as small as 5-15 microns (Pacek et al., 1994) , not as small as obtained by laser scattering instruments. However, the quality of the images for most dense crystal slurries limits the ability of imaging software to automatically identify individual particles and quantify the characteristics of these particles (e.g., maximum axis, minimum axis, aspect ratio). An advantage of online video microscopy is the direct observation of the crystals, which allows shape information to b e obtained. Also, the PVM in particular is a rugged instrument suitable for use in industrial applications. The main use of on-line video microscopy today is for qualitative troubleshooting, with only some researchers using the images for quantitative prediction (Baier and Widmer, 2000) . Recently, the on-line estimation of characteristics of the crystal shape distribution has b e e ndemonstrated, using a combination of the PVM, the FBRM, and robust chemometrics (Togkalidou et al., 2001a) . Given the importance of crystal shape in pharmaceutical applications, and that progress becomes easier as computers continue to increase in speed, the accuracy of such predictions can b eexpected to improve in future years.
ITERATIVE MODEL IDENTIFICATION AND EXPERIMENTAL DESIGN
In the past two years iterative model identi cation and experimental design has b e e napplied to several crystallization processes, including for crystals with di erent rates along di erent growth axes (Gunawan et al., 2002) . Our approach is similar to approaches used for linear lumped parameter systems, except generalized to the nonlinear distributed parameter equations needed to model pharmaceutical crystallizers (see Figure 6) . A model selection step (not shown in the gure) is used to select among di erent model structures, which correspond to di erent nucleation and/or growth mechanisms. The overall closed loop crystal product quality can b eused as the objective of the experimental design , instead of the commonly used D-optimal experimental design objective (Box et al., 1978 Miller and Rawlings, 1994) , which focuses on the uncertainty in the model parameters. Experimental design variables that have b e e noptimized b e t ween each batch experiment include the temperature pro le, antisolvent addition rates, and various characteristics of the seed distribution (Chung et al., 2000) . Accurate model parameters are typically obtained with as few as four batch crystallization experiments. A typical comparison b e t ween model predictions and measurements are shown in Figure 7 , where the moments 10 and 01 are closely related to the average length and width of rod-like crystals in the slurry. The moments were computed by weighted normalization of the FBRM data (Tadayyon and Rohani, 1998) . We have applied this approach to several pharmaceutical crystallization processes, including to the crystallization of paracetamol . It is expected that it will become increasingly common for pharmaceutical companies to identify models for use in scaling up the crystallization process. 
ROBUSTNESS ANALYSIS
Crystallization processes can have a very high sensitivity to model parameter variations (Ma et al., 1999a ). The iterative model identi cation and experimental design procedure relies heavily on the ability to quantify the e ect of model uncertainties on the crystal product quality. We developed an approach to quantify the impact of such variations on the product quality without exhaustive simulation of all possible process conditions (Ma et al., 1999b Ma and Braatz, 2001 ). The approach is applicable to nite-time nonlinear distributed parameter systems. The knowledge of the worst-case model parameters are used to determine where experimental e ort should b efocused to improve model accuracy. Robustness analysis with regard to control implementation uncertainties can guide the selection of the control instrumentation, by determining where high precision sensing and actuation are required. The computation of the worstcase external disturbances determines which disturbances signi cantly a ect the product quality. This robustness analysis has b e e napplied to several batch crystallizers, both in simulations and in experiments (Ma et al., 1999a Ma and . Robustness estimates are provided with reasonable computational requirements.
CONCLUSION
The pharmaceuticals industry is continuing to grow faster than most other industries, and most pharmaceuticals must undergo multiple crystallization steps before arriving at the nal product. Advances in measurement technologies are removing the main bottleneck that limited progress in the 1970s-1980s. Model identi cation and experimental design algorithms are b e i n g applied to pharmaceutical crystallization processes. Pharmaceutical crystallization processes have all the characteristics that make an interesting control problem|partial differential equations, nonlinear dynamics, signicant uncertainties, unmeasured state variables, signi cant disturbances, sensor noise, etc. Crystallization processes p o s ea rich array of control problems that are expected to keep control engineers engaged for some time.
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